Prescient Therapeutics Investor Update Q&A

In this session Prescient Therapeutics (ASX: PTX) CEO and Managing Director Steven Yatomi-Clarke discussed the key highlights:

• An update on Prescient’s strategy and upcoming milestones, with a focus on PTX-100.
• The journey of value creation for biotech companies, and why Prescient is on the cusp of a significant inflection point.
• Why the data from their PTX-100 Phase 1b trial is so promising.
• How the development pathway for PTX-100 could be considerably shorter and cheaper than conventional drug development paths.
• How their $18m cash position allows them to go deep into a Phase 2 trial.